News

Barr’s Alprazolam extended-release tablets will compete in a market that had total annual sales of approximately $83 million for the 12 months ending May 2006, according to data

The new formulation only needs to be taken twice a day, whereas Zyflo, the currently marketed version of zileuton, has the drawback of requiring dosing four times a

The phase IIb trial results are expected to be available towards the end of 2006 following completion of the three month follow-up period. “Patient enrolment into stroke trials

To evaluate the driving safety performance of a small group of young adults with ADHD taking medication or placebo, the researchers conducted a pilot study using a driving

Factive-5 will be marketed in the territory by Pfizer Mexico which sublicensed the rights to develop and commercialize Factive in that country from Oscient in February of this

The AZD-103 compound is a potentially disease-modifying therapeutic drug candidate for the treatment of Alzheimer’s disease. According to the company, this unique class of drug candidates may provide

The prevention of preterm birth would be a new indication for Prochieve which is currently approved and commercially available to treat infertility and secondary amenorrhea. This large-scale global

The trial, which is currently ongoing at several sites in Italy, will examine IR103, a second-generation immunotherapy, as a first-line treatment for drug-naive HIV-infected individuals not yet recommended

The open-label, dose-escalation trial is designed to assess the safety and maximum-tolerated dose of Oncaspar in combination with Gemzar in patients with these cancers. Oncaspar was initially approved